# US 2026/0275410 A1 · Methods for preparation and analysis of proximity-ligated nucleic acids from single cells

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0275410 A1
- Document ID: US20260275410A1
- Status: Published application
- Kind: A1
- Application number: 18/878,838
- Filed: 2023-06-26
- Published: 2026-09-17
- Earliest claimed: 2022-06-27
- Assignees: Arima Genomics, Inc.; New York University
- Applicants: Arima Genomics, Inc.; New York University
- Inventors: Anthony Schmitt; Soobeom Lee; Yohana Ghebrechristos; Iannis Aifantis
- Web page: https://patentgrep.com/patent/US20260275410A1

## CPC

- C12Q 1/6806: Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay (C12Q1/6804 takes precedence)
- C12Q 1/6869: Methods for sequencing
- C12N 9/1276: {RNA-directed DNA polymerase (2.7.7.49), i.e. reverse transcriptase or telomerase}
- C12N 15/1065: {Preparation or screening of tagged libraries, e.g. tagged microorganisms by STM-mutagenesis, tagged polynucleotides, gene tags}
- C12N 15/1082: {Preparation or screening gene libraries by chromosomal integration of polynucleotide sequences, HR-, site-specific-recombination, transposons, viral vectors}
- C12Q 1/6876: Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Y 207/07049: RNA-directed DNA polymerase (2.7.7.49), i.e. telomerase or reverse-transcriptase
- C40B 40/08: Libraries containing RNA or DNA which encodes proteins, e.g. gene libraries
- C40B 50/06: Biochemical methods, e.g. using enzymes or whole viable microorganisms
- C40B 70/00: Tags or labels specially adapted for combinatorial chemistry or libraries, e.g. fluorescent tags or bar codes
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Y: ENZYMES
- C40B: COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES (in silico combinatorial libraries of nucleic acids, proteins or peptides G16B35/00; in silico combinatorial chemistry G16C20/60)

## Abstract

The technology relates in part to methods for preparation and analysis of proximity-ligated nucleic acids from single cells. This technology also relates in part to single-cell workflows for multiomic analyses of chromatin interactions, accessibility, gene expression, and protein expression.

## Claims

### Claim 1

A method for preparing nucleic acid from single cells and/or single cell nuclei, comprising:
a) contacting a population of cells and/or cell nuclei with a first crosslinking agent and a second crosslinking agent, thereby generating a population of double-crosslinked cells and/or double-crosslinked cell nuclei;
b) contacting the population of cells and/or cell nuclei comprising double-crosslinked cells and/or double-crosslinked cell nuclei with one or more agents that preserve spatial-proximity relationships in the nucleic acid of the cells and/or cell nuclei; and
c) partitioning the population of cells and/or cell nuclei into partitions comprising partitioned single cells and/or partitioned single cell nuclei.

### Claim 2 (depends on 1)

The method of claim 1, wherein (a) comprises:
(i) contacting the population of cells and/or cell nuclei with the first crosslinking agent, thereby generating a population of single-crosslinked cells and/or single-crosslinked cell nuclei;
(ii) contacting the population of single-crosslinked cells and/or single-crosslinked cell nuclei with the second crosslinking agent, thereby generating a population of double-crosslinked cells and/or double-crosslinked cell nuclei.

### Claim 3 (depends on 1)

The method of claim 1, wherein the first crosslinking agent comprises formaldehyde or disuccinimidyl glutarate (DSG).

### Claim 4 (depends on 1)

The method of claim 1, wherein the second crosslinking agent comprises formaldehyde or disuccinimidyl glutarate (DSG).

### Claim 5 (depends on 1)

The method of claim 1, wherein the first crosslinking agent comprises formaldehyde and the second crosslinking agent comprises disuccinimidyl glutarate (DSG).

### Claim 6 (depends on 1)

The method of claim 1, wherein (b) comprises contacting the population of cells and/or cell nuclei with one or more reagents that generate proximity ligated nucleic acid molecules.

### Claim 7 (depends on 1)

The method of claim 1, wherein (b) comprises contacting the population of cells and/or cell nuclei with one or more restriction endonucleases.

### Claim 8 (depends on 7)

The method of claim 7, wherein the one or more restriction endonucleases yield fragment sizes that average about 800 base pairs.

### Claim 9 (depends on 7)

The method of claim 7, wherein (b) comprises contacting the population of cells and/or cell nuclei with one or more restriction endonucleases for more than 2 hours.

### Claim 10 (depends on 9)

The method of claim 9, wherein (b) comprises contacting the population of cells and/or cell nuclei with one or more restriction endonucleases for more than 8 hours.

### Claim 11 (depends on 7)

The method of claim 7, wherein (b) comprises contacting the population of cells and/or cell nuclei with two or more restriction endonucleases.

### Claim 12 (depends on 1)

The method of claim 1, wherein (b) comprises contacting the population of cells and/or cell nuclei with a ligase.

### Claim 13 (depends on 1)

The method of claim 1, wherein (b) comprises contacting the population of cells and/or cell nuclei with a junction marker.

### Claim 14 (depends on 1)

The method of claim 1, further comprising after (b) and prior to (c), contacting the population of cells and/or cell nuclei with one or more agents that enrich for accessible chromatin.

### Claim 15 (depends on 14)

The method of claim 14, wherein the one or more agents that enrich for accessible chromatin comprise a transposase.

### Claim 16 (depends on 15)

The method of claim 15, wherein the transposase is a Tn5 transposase.

### Claim 17 (depends on 14)

The method claim 14, wherein the one or more agents that enrich for accessible chromatin further comprise one or more oligonucleotides.

### Claim 18 (depends on 17)

The method of claim 17, wherein the one or more oligonucleotides comprise sequencing primer sequences.

### Claim 19 (depends on 14)

The method of claim 14, wherein the one or more agents that enrich for accessible chromatin are in a salt solution.

### Claim 20 (depends on 19)

The method of claim 19, wherein the salt is present at a concentration of about 50 mM to about 200 mM.

### Claim 21 (depends on 19)

The method of claim 19, wherein the salt is NaCl.

### Claim 22 (depends on 1)

The method of claim 1, wherein the method further comprises prior to (a), contacting the population of cells and/or cell nuclei with a cell-surface protein binding agent.

### Claim 23 (depends on 22)

The method of claim 22, wherein the binding agent comprises one or more antibodies.

### Claim 24 (depends on 23)

The method claim 23, wherein one or more of the antibodies are conjugated to an oligonucleotide.

### Claim 25 (depends on 1)

The method of claim 1, wherein the cells and/or cell nuclei are partitioned into droplets in (c).

### Claim 26 (depends on 25)

The method of claim 25, wherein (c) comprises contacting the population of cells and/or cell nuclei with gel bead-in-emulsion (GEM) and one or more cell-specific and/or nucleus-specific barcode oligonucleotide species.

### Claim 27 (depends on 1)

The method of claim 1, wherein the cells and/or cell nuclei are partitioned into wells in (c).

### Claim 28 (depends on 1)

The method of claim 1, further comprising after (c), performing a heated crosslink reversal process.

### Claim 29 (depends on 28)

The method of claim 28, further comprising after the heated crosslink reversal process, contacting cells and/or cell nuclei in the one or more partitions with an agent comprising a reverse transcriptase activity, thereby generating cDNA from mRNA present in the cells and/or cell nuclei in the one or more partitions.

### Claim 30 (depends on 1)

The method of claim 1, further comprising after (c) generating one or more nucleic acid libraries from one or more of the cells and/or cell nuclei in the partitions.

### Claim 31 (depends on 30)

The method of claim 30, wherein the one or more nucleic acid libraries comprise one or more nucleic acid library molecule species chosen from:
i) library molecules comprising accessible chromatin fragments;
ii) library molecules comprising accessible chromatin fragments and proximity ligated chromatin fragments;
iii) library molecules comprising oligonucleotides representing protein expression; and
iv) library molecules comprising cDNA fragments representing gene expression.

### Claim 32 (depends on 30)

The method of claim 30, further comprising sequencing the one or more nucleic acid libraries, thereby generating sequence reads.

### Claim 33 (depends on 32)

The method of claim 32, further comprising analyzing the sequence reads according to a sequence read analysis.

### Claim 34 (depends on 33)

The method of claim 33, wherein the sequence read analysis comprises identifying spatial-proximity relationship information.

### Claim 35 (depends on 33)

The method of claim 33, wherein the sequence read analysis comprises identifying accessible chromatin information.

### Claim 36 (depends on 33)

The method of claim 33, wherein the sequence read analysis comprises identifying protein expression information.

### Claim 37 (depends on 33)

The method of claim 33, wherein the sequence read analysis comprises identifying gene expression information.

### Claim 38 (depends on 1)

The method of claim 1, wherein cells and/or cell nuclei in the partitions comprise proximally ligated chromatin contacts (PLCC).

### Claim 39 (depends on 38)

The method of claim 38, further comprising determining an amount of proximally ligated chromatin contacts (PLCC) per cell and/or cell nucleus.

### Claim 40 (depends on 39)

The method of claim 39, wherein the PLCC per cell and/or cell nucleus is greater than the PLCC per cell and/or cell nucleus obtained under conditions in which single-crosslinked cells and/or single-crosslinked cell nuclei are subjected to conditions that preserve spatial-proximity relationships.

### Claim 41 (depends on 39)

The method of claim 39, wherein the PLCC per cell and/or cell nucleus is about 5,000 or greater.

### Claim 42 (depends on 39)

The method of claim 39, further comprising determining a percentage of proximally ligated chromatin contacts (PLCC).

### Claim 43 (depends on 42)

The method of claim 42, wherein the percentage of PLCC is greater than the percentage of PLCC obtained under conditions in which single-crosslinked cells and/or single-crosslinked cell nuclei are subjected to conditions that preserve spatial-proximity relationships.

### Claim 44 (depends on 1)

The method of claim 1, wherein a subset of partitions comprise two or more cells and/or cell nuclei.

### Claim 45 (depends on 44)

The method of claim 44, wherein:
the subset of partitions comprising two more cells and/or cell nuclei comprises partitions each associated with a single barcode; and
a multiplet rate is a fraction of barcodes associated with two or more cells and/or cell nuclei.

### Claim 46 (depends on 45)

The method of claim 45, further comprising determining the multiplet rate.

### Claim 47 (depends on 46)

The method of claim 46, wherein the multiplet rate is less than the multiplet rate obtained under conditions in which single-crosslinked cells and/or single-crosslinked cell nuclei are subjected to conditions that preserve spatial-proximity relationships.

### Claim 48 (depends on 47)

The method of claim 47, wherein the multiplet rate is less than about 8%.

### Claim 49

A kit comprising:
a) a first crosslinking agent;
b) a second crosslinking agent; and
c) one or more agents that preserve spatial-proximity relationships in nucleic acid of cells and/or cell nuclei.

### Claim 50 (depends on 49)

The kit of claim 49, further comprising one or more agents for partitioning a population of cells and/or cell nuclei into partitions comprising partitioned single cells and/or partitioned single cell nuclei.

### Claim 51 (depends on 49)

The kit of claim 49, wherein the first crosslinking agent comprises formaldehyde or disuccinimidyl glutarate (DSG).

### Claim 52 (depends on 49)

The kit of claim 49, wherein the second crosslinking agent comprises formaldehyde or disuccinimidyl glutarate (DSG).

### Claim 53 (depends on 49)

The kit of claim 49, wherein the first crosslinking agent comprises formaldehyde and the second crosslinking agent comprises disuccinimidyl glutarate (DSG).

### Claim 54 (depends on 49)

The kit of claim 49, wherein the one or more agents that preserve spatial-proximity relationships in the nucleic acid of the cells and/or cell nuclei comprise one or more reagents that generate proximity ligated nucleic acid molecules.

### Claim 55 (depends on 49)

The kit of claim 49, wherein the one or more agents in (c) comprise one or more restriction endonucleases.

### Claim 56 (depends on 49)

The kit of claim 49, wherein the one or more agents in (c) comprise two or more restriction endonucleases.

### Claim 57 (depends on 49)

The kit of claim 49, wherein the one or more agents in (c) comprise a ligase.

### Claim 58 (depends on 49)

The kit of claim 49, wherein the one or more agents in (c) comprise a junction marker.

### Claim 59 (depends on 49)

The kit of claim 49, further comprising one or more agents that enrich for accessible chromatin.

### Claim 60 (depends on 59)

The kit of claim 59, wherein the one or more agents that enrich for accessible chromatin comprise a transposase.

### Claim 61 (depends on 60)

The kit of claim 60, wherein the transposase is a Tn5 transposase.

### Claim 62 (depends on 59)

The kit of claim 59, wherein the one or more agents that enrich for accessible chromatin further comprise one or more oligonucleotides.

### Claim 63 (depends on 62)

The kit of claim 62, wherein the one or more oligonucleotides comprise sequencing primer sequences.

### Claim 64 (depends on 59)

The kit of claim 59, wherein the one or more agents that enrich for accessible chromatin are in a salt solution.

### Claim 65 (depends on 64)

The kit of claim 64, wherein the salt is present at a concentration of about 50 mM to about 200 mM.

### Claim 66 (depends on 64)

The kit of claim 64, wherein the salt is NaCl.

### Claim 67 (depends on 49)

The kit of claim 49, further comprising a cell-surface protein binding agent.

### Claim 68 (depends on 67)

The kit of claim 67, wherein the binding agent comprises one or more antibodies.

### Claim 69 (depends on 68)

The kit of claim 68, one or more of the antibodies are conjugated to an oligonucleotide.

### Claim 70 (depends on 50)

The kit of claim 50, wherein the one or more agents for partitioning a population of cells and/or cell nuclei into partitions comprise gelbead-in-emulsion (GEM) and one or more cell-specific and/or nucleus-specific barcode oligonucleotide species.

### Claim 71 (depends on 49)

The kit of claim 49, further comprising an agent comprising a reverse transcriptase activity.

### Claim 72 (depends on 49)

The kit of claim 49, further comprising one or more agents for generating one or more nucleic acid libraries.

### Claim 73

A method for preparing nucleic acid from single cells and/or single cell nuclei, comprising:
a) contacting a population of cells and/or cell nuclei with one or more antibodies conjugated to an oligonucleotide;
b) contacting the population of cells and/or cell nuclei with a first crosslinking agent and a second crosslinking agent, thereby generating a population of double-crosslinked cells and/or double-crosslinked cell nuclei, wherein the first crosslinking agent comprises formaldehyde and the second crosslinking agent comprises disuccinimidyl glutarate (DSG);
c) contacting the population of cells and/or cell nuclei comprising double-crosslinked cells and/or double-crosslinked cell nuclei with one or more agents that generate proximity ligated nucleic acid molecules in the nucleic acid of the cells and/or cell nuclei, wherein the one or more reagents comprise two or more restriction endonucleases and a ligase;
d) contacting the population of cells and/or cell nuclei with one or more agents that enrich for accessible chromatin, wherein the one or more agents comprise a Tn5 transposase and one or more oligonucleotides comprising sequencing primer sequences;
e) partitioning the population of cells and/or cell nuclei into droplet partitions comprising partitioned single cells and/or partitioned single cell nuclei, wherein the partitioning comprises contacting the population of cells and/or cell nuclei with gelbead-in-emulsion (GEM) and one or more cell-specific and/or nucleus-specific barcode oligonucleotide species;
f) performing a heated crosslink reversal process and contacting cells and/or cell nuclei in the one or more partitions with an agent comprising a reverse transcriptase activity, thereby generating cDNA from mRNA present in the cells and/or cell nuclei in the one or more partitions; and
g) generating one or more nucleic acid libraries from one or more of the cells and/or cell nuclei in the partitions, wherein the one or more nucleic acid libraries comprise:
i) library molecules comprising accessible chromatin fragments;
ii) library molecules comprising accessible chromatin fragments and proximity ligated chromatin fragments;
iii) library molecules comprising oligonucleotides representing protein expression; and
iv) library molecules comprising cDNA fragments representing gene expression.

### Claim 74 (depends on 73)

The method of claim 73, wherein the one or more agents in (c) comprise a junction marker.
